Neon Therapeutics
215 First Street
Cambridge
Massachusetts
02142
United States
Tel: 617-337-4701
Website: http://neontherapeutics.com/
Email: info@neontherapeutics.com
About Neon Therapeutics
NEON Therapeutics is focused on unlocking the full potential of the immune system to recognize and attack cancer.
YEAR FOUNDED:
2015
LEADERSHIP:
Founders: James Allison, Ed Fritsch, Nir Hacohen, and Eric Lander
CEO: Hugh O'Dowd
CBO: Robert Ang
CTO: ED Fritsch
CMO: Barbara Weber
CFO: Daniella Beckman
JOBS:
Please click here for Neon job opportunities.
51 articles about Neon Therapeutics
-
For those looking for work, it’s good to know that some positions are in such demand that employers are falling all over themselves to offer hiring incentives. That’s the case with the biotech sector in Massachusetts, as many companies are dangling almost unheard-of benefits as incentives.
-
Neon Therapeutics to Present Data from Ongoing Phase 1b NT-001 Clinical Trial at the European Society for Medical Oncology 2018 CongressCompany to Host Investor Conference Call and Webcast on October 22, 2018 at 8:00 a.m. ET
10/3/2018
Neon Therapeutics, Inc. will be presented in an upcoming oral presentation at the European Society for Medical Oncology (ESMO) 2018 Congress taking place October 19-23, 2018 in Munich, Germany.
-
Neon Therapeutics to Present at the Society for Immunotherapy of Cancer 33rd Annual Meeting
10/1/2018
Neon Therapeutics, Inc. (Nasdaq: NTGN), a clinical-stage immuno-oncology company developing neoantigen-based therapeutics, today announced upcoming presentations at the Society for Immunotherapy of Cancer (SITC) 33rd Annual Meeting, taking place November 9-11, 2018 in Washington, D.C.
-
According to BioPharmCatalyst, there have been (or soon will be) 58 biopharma initial public offerings (IPOs) in 2018, and there’s still more than three months to go.
-
Merus Announces Formation of a Scientific Advisory Board
8/22/2018
Merus N.V. (Nasdaq:MRUS), a clinical-stage immuno-oncology company developing innovative bispecific antibody therapeutics (Biclonics®), today announced the formation of a Scientific Advisory Board (SAB), consisting of several world-renowned immuno-oncology and drug development professionals.
-
It’s been a pretty good year for mergers and acquisitions in the biopharma industry. But the landscape for IPOs has been excellent as well, particularly in Massachusetts, which has recorded 13 IPOs since the beginning of the year.
-
Cambridge, Massachusetts-based Neon Therapeutics is launching an initial public offering (IPO) of 6,250,000 shares of common stock at a price offering of $16 per share.
-
Eight biotechs launched initial public offerings (IPO) in May, April wasn’t as hot a month, with only two. But June is off to a good start with two.
-
Neon Therapeutics filed with the U.S. Securities and Exchange Commission (SEC) for an initial public offering (IPO) and hopes to raise $115 million.
-
Rheos Medicines, backed by Third Rock Ventures, launched with a $60 million Series A financing. The company will focus on immunometabolism to treat disease.
-
Neon Therapeutics Expands Board of Directors With Leading Experts in Cancer Drug Discovery and Corporate Finance
12/12/2017
Neon Therapeutics announced the expansion of the company’s Board of Directors with the addition of leading experts in translational cancer drug discovery and corporate finance.
-
Denali Raises a Mountain of Cash
12/12/2017
A look at what three ex-Genentech employees have accomplished at Denali so far. -
Neon Therapeutics Announces Clinical Trial Collaboration With Merck
12/7/2017
Neon Therapeutics and Merck will collaborate on a Phase 1b clinical trial that will examine the safety, tolerability and preliminary efficacy of NEO-PV-01 in combination with KEYTRUDA, pemetrexed and carboplatin in patients with untreated advanced or metastatic nonsquamous non-small cell lung cancer (NSCLC).
-
The company announced the successful completion of an additional $36 million extension to its Series B financing.
-
Vedantra Pharmaceuticals Extends Research Collaboration With Neon Therapeutics to Develop Novel Cancer Immunotherapies
11/1/2017
Under the extended agreement, Vedantra and Neon will continue to build on research exploring the potential benefits of combining Vedantra's cutting-edge, lymph node targeting amphiphile technology with Neon's innovative capabilities in neoantigen vaccine research.
-
Neon Therapeutics Enters License Agreement With The Netherlands Cancer Institute (NCI) For Neoantigen-Based T Cell Therapeutics
10/4/2017
-
Ms. Teresa Regan Joins Neon Therapeutics As VP Of Human Resources
8/15/2017
-
Neon Therapeutics And Apexigen Announce Immuno-Oncology Clinical Trial Collaboration
7/25/2017
-
CRISPR And Neon Therapeutics Enter Research Collaboration
7/10/2017
-
Dr. Yasir Al-Wakeel Joins Neon Therapeutics As Chief Financial Officer
6/16/2017